Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients

Overexpression of human epidermal growth factor receptor-2 (HER2) in metastatic breast cancer (MBC) is associated with poor prognosis. This single-arm open-label trial (EGF109491; NCT00508274) was designed to confirm the efficacy and safety of lapatinib in combination with capecitabine in 52 heavily...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Bing-He, Jiang, Ze-Fei, Chua, Daniel, Shao, Zhi-Min, Luo, Rong-Cheng, Wang, Xiao-Jia, Liu, Dong-Geng, Yeo, Winnie, Yu, Shi-Ying, Newstat, Beth, Preston, Alka, Martin, Anne-Marie, Chi, Hai-Dong, Wang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sun Yat-sen University Cancer Center 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013397/
https://www.ncbi.nlm.nih.gov/pubmed/21527065
http://dx.doi.org/10.5732/cjc.010.10507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013397/
https://www.ncbi.nlm.nih.gov/pubmed/21527065
http://dx.doi.org/10.5732/cjc.010.10507

Ejemplares similares